In This Article:
Over the last 7 days, the United States market has dropped by 1.2%, yet it has risen by an impressive 30% over the past year, with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying stocks that are perceived as undervalued and have insider buying can be a promising strategy for investors looking to capitalize on potential growth opportunities.
Top 10 Undervalued Small Caps With Insider Buying In The United States
Name | PE | PS | Discount to Fair Value | Value Rating |
---|---|---|---|---|
Capital Bancorp | 14.1x | 2.9x | 48.35% | ★★★★☆☆ |
Franklin Financial Services | 10.5x | 2.1x | 31.63% | ★★★★☆☆ |
HighPeak Energy | 11.4x | 1.6x | 33.33% | ★★★★☆☆ |
Pebblebrook Hotel Trust | NA | 1.0x | 12.62% | ★★★★☆☆ |
German American Bancorp | 16.3x | 5.4x | 43.76% | ★★★☆☆☆ |
USCB Financial Holdings | 18.9x | 5.4x | 48.98% | ★★★☆☆☆ |
First United | 13.8x | 3.1x | 46.34% | ★★★☆☆☆ |
Orion Group Holdings | NA | 0.4x | -235.34% | ★★★☆☆☆ |
Community West Bancshares | 18.7x | 2.9x | 42.25% | ★★★☆☆☆ |
Tilray Brands | NA | 1.5x | -76.94% | ★★★☆☆☆ |
Let's uncover some gems from our specialized screener.
ACNB
Simply Wall St Value Rating: ★★★☆☆☆
Overview: ACNB is a financial services company primarily engaged in banking and insurance operations, with a market capitalization of $0.29 billion.
Operations: The company's primary revenue streams are from its banking and insurance segments, with banking contributing significantly more. Operating expenses are a major cost component, consistently exceeding $60 million in recent periods. The net income margin has shown variability, reaching as high as 34.31% in June 2023 before declining to 27.58% by September 2024.
PE: 13.7x
ACNB Corporation, a smaller company by market capitalization, has recently shown insider confidence with share purchases. Despite a decrease in net income to US$7.2 million for Q3 2024 from US$9.04 million the previous year, the company maintains its appeal through strategic buybacks and dividend growth, increasing its quarterly dividend by 6.7% to US$0.32 per share. Looking ahead, earnings are projected to grow at an annual rate of 18.75%, suggesting potential for future value appreciation despite current challenges.
Maravai LifeSciences Holdings
Simply Wall St Value Rating: ★★★★★☆
Overview: Maravai LifeSciences Holdings specializes in providing products and services for nucleic acid production and biologics safety testing, with a market capitalization of $1.88 billion.
Operations: Nucleic Acid Production is the primary revenue stream, generating $213.27 million, followed by Biologics Safety Testing at $63.65 million. The company has experienced fluctuations in its net income margin, with recent periods showing a decline to -81.13%. Gross profit margin also saw a decrease from 83.33% in early 2022 to 46.36% by late 2024.